Wedbush is removing Vridian Therapeutics from the Best Ideas List due to the firm’s investment price discipline. Wedbush has an Outperform rating on the shares with a price target of $37.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian: Pullback Seen as Overdone as Veligrotug Convenience and TED Portfolio Underscore Buy Rating
- Leerink sees weakness in Viridian Therapeutics shares as ‘overdone’
- Buy Rating on Viridian: Elegrobart’s Convenience Edge and Overdone Share Price Pullback in Thyroid Eye Disease
- Midday Fly By: Neurocrine to acquire Soleno, Oracle hires new CFO
- Viridian sinks after Amgen thyroid eye disease study hits endpoints